Physician profile
Robert J Stratton
NPI 1679795348
$2,186.70
in general payments reported to CMS, 2019-2025
14 companies · $521 in 2025
The $521 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $140 · 2022: $316 · 2023: $622 · 2024: $588 · 2025: $521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,731.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,730.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $789.15 | 2021-2025 | Vivitrol, Vivitrol |
| Novo Nordisk INC | $231.06 | 2022-2023 | Wegovy |
| Janssen Pharmaceuticals, INC | $198.01 | 2022-2024 | Invega Trinza, Invega Sustenna |
| Neurocrine Biosciences, INC. | $146.98 | 2025 | |
| Sobi, INC | $125.00 | 2023 | |
| Axsome Therapeutics, INC. | $121.86 | 2023 | Auvelity |
| Amgen INC. | $109.64 | 2024 | Evenity |
| Lilly USA, LLC | $109.31 | 2024 | Mounjaro |
| Gilead Sciences, INC. | $97.79 | 2023 | Epclusa |
| Abbvie INC. | $89.46 | 2021 | |
| Indivior INC. | $84.90 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $36.49 | 2023-2025 | Abilify Asimtufii, Abilify Maintena |
| E.R. Squibb & Sons, L.L.C. | $33.40 | 2025 | Cobenfy |
| Braeburn INC. | $13.65 | 2025 | Brixadi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Stratton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.